United States securities and exchange commission logo





                          October 20, 2021

       Anders Vadsholt
       Chief Financial Officer
       Orphazyme A/S
       Ole Maal  es Vej 3
       DK-2200 Copenhagen

                                                        Re: Orphazyme A/S
                                                            Registration
Statement on Form F-3
                                                            Filed October 15,
2021
                                                            File No. 333-260283

       Dear Mr. Vadsholt:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tyler
Howes at 202-551-3370 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Joshua A. Kaufman, Esq.